



₹1,600 Crore Approved for 41 Pharma & MedTech Innovation Projects under PRIP First Round

Projects include Innovations from Novel Drug Discovery to Advanced Medical Technologies

₹4,620 Crore in Pharma & MedTech R&D cumulative Investment

Posted On: 30 SEP 2026 7:40PM by PIB Delhi

Under the **first call** of the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), **41 projects** have been approved for around **₹1,600 crore** in financial assistance. The approved projects are expected to catalyse an additional **₹3,020 crore** of private investment, taking the **total R&D** investment across these projects to around **₹4,620 crore**. The approved portfolio spans the innovation value chain, covering novel drug discovery, clinical development and innovative medical technologies.

Of the 41 projects approved so far, **12 are at an early stage** and **29 are at a later stage**. **Nineteen projects** are being undertaken by **startups and MSMEs**, while **22** are being undertaken by **large companies**. In terms of priority areas, **27 projects** fall under New Medicines, **five under Complex Generics and Biosimilars**, and nine under **Novel Medical Devices**.

These projects demonstrate a shift from a predominantly volume-driven pharmaceutical model towards innovation-led, technology-intensive model, bringing together established pharmaceutical companies, biotechnology enterprises and MedTech innovators.

The portfolio includes projects by companies and innovators such as *Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology and Bugworks Research*. The projects demonstrate a wide range of innovation supported under PRIP, including **first-in-class innovations, emerging technologies**, innovations with potential for global markets and strategic priority innovations addressing areas of high public health importance. Projects supported under these categories include an **antibacterial targeting multidrug-resistant Gram-negative infections**, an **exosome-based regenerative therapy for corneal disease**, an **in-vivo CAR-T platform**, **patient-derived breast cancer organoids**, a **programmable RNA-targeting antiviral technology**, **portable plasmonic-PCR for point-of-care infection diagnosis** and a **microfluidic platform for TB detection**.

Under the **strategic priority framework**, enhanced support is available for innovations addressing areas such as **neglected tropical diseases, rare diseases, AMR for India-priority pathogens, pathogens with outbreak or pandemic potential**, and **vaccines for vaccine-preventable diseases**. Six projects have been approved under this framework so far, including projects relating to bacterial pneumonia/meningitis, dengue, influenza and next-generation TB vaccines. Evaluation of the remaining applications under the first round is underway, with further results to be announced over the coming month.

PC/PM

(Release ID: 2317296) Visitor Counter : 613

Read this release in: Telugu , Urdu , हिन्दी